ClinicalTrials.gg
Not yet recruitingNCT07361523Updated Jan 23, 2026

Using Near-Infrared Spectroscopy Devices to Assess Myocardial and Visceral Perfusion During Complex Congenital Cardiac Surgery

An observational study in Congenital Heart Disease, sponsored by Boston Children's Hospital. Not yet recruiting. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Boston Children's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Defects, Congenital by Boston Children's Hospital — 9 open to participants now, 10 under way, none of them phase 3. Heart Defects, Congenital · Boston Children's Hospital.

Planned enrollment
14th of 19
50 · median 64
Started
2026
with 2 others
Observational
19 of 37
8 open now
Registered
36th of 37
by date

Among the 37 studies in Heart Defects, Congenital by Boston Children's Hospital, this one is the 14th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2026, is one of 19 observational ones, and was the 36th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

9 of the 37 studies in Heart Defects, Congenital by Boston Children's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Defects, Congenital by Boston Children's Hospital, or all of them as a file.
02

Study summary

The use of near infrared spectroscopy (NIRS) is a technique that has recently been incorporated by several other surgical specialties to measure tissue perfusion, such as in plastic surgery to allow for earlier detection of free flap vascular compromise in the postoperative monitoring protocol, with promising outcomes. IntraOx is a handheld oximeter that uses NIRS to measure tissue oxygen saturation and that has been used as an alternative to indocyanine green (ICG) to assess bowel perfusion in colorectal anastomotic cases. IntraOx is a promising technology that is also sterile and easy to use that can be incorporated into congenital heart surgery procedures to evaluate myocardial perfusion in a time sensitive manner. This technology could also be used on the liver to assess systemic perfusion as another indicator of cardiac function, in conjunction with the intraoperative transesophageal echocardiography (TEE). This could provide more concrete data about not only myocardial perfusion, but systemic perfusion as well. This data could be critical to help surgeons make surgical decisions and may help to improve patient outcomes.

This will be a prospective review of the use of the Intra.Ox device during cardiac surgery at different timepoints during the procedure to assess perfusion. This device is FDA-approved for use in adults but not approved for use in children and will be investigational in children.

The primary objective of this study is to test whether the Intra.Ox (Vioptix Inc.) using near-infrared spectroscopy to measure tissue oxygen saturation can be used to evaluate myocardial and visceral perfusion at different time points during complex congenital heart surgery, and particularly those involving coronary artery manipulation such as patients undergoing arterial switch operations or stage 1 palliation for hypoplastic left heart syndrome. The investigators would also use this device on the liver to assess systemic perfusion. The secondary objective is to evaluate whether the investigators would be able to use the information from the Intra.Ox device to make clinical decisions that can improve patient outcomes.

03

Conditions studied

  • Congenital Heart Disease
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over 1 year of age undergoing congenital heart surgery at Boston Children's Hospital identified by the PI and the study coordinator to have concern for decreased myocardial and peripheral perfusion for any reason. This may include, but will not be limited to, patients with history of myocardial ischemia, surgical procedures on the coronary arteries or operating near the coronary arteries that may impact myocardial perfusion, surgical procedures that may impact systemic perfusion, patients with history of coronary artery disease, patients with history of angina, patients with history of rheumatic disease that may impact perfusion, and patients with previous history of poor ventricular function, arrhythmia, or other complications following cardiopulmonary bypass.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 1 year of age undergoing congenital heart surgery at Boston Children's Hospital are all eligible for participation in this study.
  • All subjects undergoing congenital heart surgery at Boston Children's Hospital will be screened for inclusion in this study. Screening will prioritize identifying patients with concern for decreased myocardial and peripheral perfusion for any reason, as designated by Dr. Sitaram Emani's clinical judgement.
  • Eligibility will be reviewed in advance by screening upcoming surgical procedures. All patients over 1 year of age will be eligible for participation in this study and screened for inclusion. Any patient at risk for malperfusion during bypass (e.g. Fontans, biventricular repair, long cross-clamp times, etc.) will be identified ahead of time and prioritized for inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Any records flagged for "research opt out."
  • Neonates and children undergoing surgery less than 1 year of age
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • IntraOx Device Patients

    Pediatric patients undergoing congenital heart surgery with risk for myocardial or peripheral ischemia with use of IntraOx device intraoperatively to assess myocardial and visceral perfusion at 4 different time points

    Device: Tissue oximeter (IntraOx)

Interventions

  • DeviceTissue oximeter (IntraOx)

    The Intra.Ox device will be used to measure %StO2 readings taken at different time points during the surgery, including: (1) prior to bypass when the heart is being perfused by the coronary arteries, (2) after the patient is placed on cardiopulmonary bypass (CPB) but prior to placing a cross-clamp, (3) after placing a cross-clamp when the heart is not being perfused by CPB, and (4) after the patient is taken off CPB and the heart is re-perfusing. These readings will not impact the surgical management of the patient, and the congenital heart surgery will be carried out per standard of care according to the judgement of the surgeon.

06

What researchers measure

Primary outcomes

  1. Oxygen saturation

    Oxygen saturation levels measured from: pulse oximetry, tissue oximeter, arterial blood gases, and venous blood gases in units of %

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  2. Liver function test: ALP

    Post-operative liver function tests: Alkaline Phosphatase (ALP) in units of International Units per liter (U/L or IU/L) as a measure of the effects of systemic perfusion

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  3. Liver Function Test: AST

    Post-operative liver function test: AST (Aspartate Aminotransferase) in units of International Units per liter (U/L or IU/L) as a measure of the effects of systemic perfusion

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  4. Liver function Test: ALT

    Post-operative liver function test: ALT (Alanine Transaminase) in units of International Units per liter (U/L or IU/L) as a measure of the effects of systemic perfusion

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  5. Cardiac function

    Measuring cardiac function as measured by ejection fraction (in %) in post-operative echocardiogram results.

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  6. Kidney function

    Laboratory values of BUN and Creatinine (Cr) in units of mg/dL as a measurement of kidney function and perfusion

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  7. Mortality and major complications

    Major complications as defined by the STS and Congenital Heart Surgeons Society including renal failure requiring dialysis, permanent neurologic deficit, pacemaker, paralyzed diaphragm, mechanical circulatory support, and unplanned reintervention. This will be recorded as one outcome (whether or not a patient had mortality and major complications) and not measuring multiple multiple assessments; it is a quantitative assessment of whether or not a patient encountered one of the major complications or mortality as defined above. There are no units of measure.

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  8. Lactate

    Lactate levels in mmol/L as measurement for tissue perfusion.

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  9. pH

    pH from arterial blood gas and venous blood gas to measure blood acidity/alkalinity.

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  10. Blood gas: PaO2

    PaO2 (partial pressures of oxygen) in mmHg from arterial and venous blood gas blood tests

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  11. Blood Gas: PaCO2

    PaCO2 (partial pressures of carbon dioxide) in mmHg from arterial and venous blood gas blood tests

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  12. Bicarbonate

    Bicarbonate values from arterial and venous blood gas in units of mmol/L. This is one outcome measure that will be recorded, not multiple assessments with different units of measure. Bicarbonate values will be recorded from two different blood gas sources in mmol/L.

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  13. Echocardiography qualitative descriptions

    Measurement and recording of qualitative written report from cardiologist interpretation of echocardiography, specifically assessing for reports of 1) valvular dysfunction (regurgitation or stenosis), 2) myocardial dysfunction, hypokinesis, filling defects, etc. or 3) any other abnormalities written in qualitative report relating to cardiac function

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  14. Lactate

    Lactate levels in mmol/L as measurement for tissue perfusion

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

Secondary outcomes

  1. Intensive care unit length of stay

    Intensive care unit length of stay in days

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  2. Hospital length of stay

    Hospital length of stay of stay in days

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  3. Liver function tests: bilirubin

    Measurements of bilirubin in units of mg/dL to assess liver function as indicator of tissue perfusion

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  4. Liver function test: protein

    Total protein in g/dL as measure of liver function

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  5. Liver function test: albumin

    Albumin in g/dL as measure of liver function

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  6. Electrolytes: sodium

    Basic metabolic panel laboratory value measuring sodium in units of mEq/L

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  7. Electrolytes: potassium

    Basic metabolic panel laboratory values measuring potassium in units of mEq/L

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  8. Electrolytes: chloride

    Basic metabolic panel laboratory values measuring chloride in units of mEq/L

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  9. Electrolytes: CO2

    Basic metabolic panel laboratory values measuring CO2 in units of mEq/L

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  10. Basic metabolic panel: glucose

    Basic metabolic panel glucose levels in units of mg/dL

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  11. Basic metabolic panel: calcium

    Basic metabolic panel calcium levels in units of mg/dL

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  12. Aortic valve diameter

    Aortic heart valve annulus diameters measured in mm

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  13. Mitral valve diameter

    Mitral valve annulus diameters measured in mm

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  14. Pulmonary valve diameter

    Pulmonary valve annulus diameters measured in mm

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  15. Tricuspid valve diameter

    Tricuspid valve annulus diameters measured in mm

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  16. Heart valve pressure gradient: aortic valve

    Pressure gradients across aortic valve measured on echocardiography measured in mmHg

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  17. Heart valve pressure gradient: mitral valve

    Pressure gradients across mitral valve measured on echocardiography measured in mmHg

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  18. Heart valve pressure gradient: tricuspid valve

    Pressure gradients across tricuspid valve measured on echocardiography measured in mmHg

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

  19. Heart valve pressure gradient: pulmonic valve

    Pressure gradients across pulmonic valve measured on echocardiography measured in mmHg

    Time frame: Day 0 ("baseline") up to 2 weeks post-operation

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pasquali SK, Shahian DM, O'Brien SM, Jacobs ML, Gaynor JW, Romano JC, Gaies MG, Hill KD, Mayer JE, Jacobs JP. Development of a Congenital Heart Surgery Composite Quality Metric: Part 1-Conceptual Framework. Ann Thorac Surg. 2019 Feb;107(2):583-589. doi: 10.1016/j.athoracsur.2018.07.037. Epub 2018 Sep 15. PubMed 30227127 ↗
  • Jacobs JP, Jacobs ML, Austin EH 3rd, Mavroudis C, Pasquali SK, Lacour-Gayet FG, Tchervenkov CI, Walters H 3rd, Bacha EA, Nido PJ, Fraser CD, Gaynor JW, Hirsch JC, Morales DL, Pourmoghadam KK, Tweddell JS, Prager RL, Mayer JE. Quality measures for congenital and pediatric cardiac surgery. World J Pediatr Congenit Heart Surg. 2012 Jan 1;3(1):32-47. doi: 10.1177/2150135111426732. PubMed 23804682 ↗
  • Koolen PGL, Vargas CR, Ho OA, Ibrahim AMS, Ricci JA, Tobias AM, Winters HAH, Lin SJ, Lee BT. Does Increased Experience with Tissue Oximetry Monitoring in Microsurgical Breast Reconstruction Lead to Decreased Flap Loss? The Learning Effect. Plast Reconstr Surg. 2016 Apr;137(4):1093-1101. doi: 10.1097/01.prs.0000481071.59025.82. PubMed 27018663 ↗
  • Oskarsson G, Pesonen E, Munkhammar P, Sandstrom S, Jogi P. Normal coronary flow reserve after arterial switch operation for transposition of the great arteries: an intracoronary Doppler guidewire study. Circulation. 2002 Sep 24;106(13):1696-702. doi: 10.1161/01.cir.0000030937.27602.bd. PubMed 12270865 ↗
  • Yates RW, Marsden PK, Badawi RD, Cronin BF, Anderson DR, Tynan MJ, Maisey MN, Baker EJ. Evaluation of myocardial perfusion using positron emission tomography in infants following a neonatal arterial switch operation. Pediatr Cardiol. 2000 Mar-Apr;21(2):111-8. doi: 10.1007/s002469910015. PubMed 10754077 ↗
  • Noel CV, Krishnamurthy R, Masand P, Moffett B, Schlingmann T, Cheong BY, Krishnamurthy R. Myocardial Stress Perfusion MRI: Experience in Pediatric and Young-Adult Patients Following Arterial Switch Operation Utilizing Regadenoson. Pediatr Cardiol. 2018 Aug;39(6):1249-1257. doi: 10.1007/s00246-018-1890-z. Epub 2018 May 10. PubMed 29748700 ↗
  • Sherwinter D, Chandler P, Martz J. The use of tissue oxygen measurements compared to indocyanine green imaging for the assessment of intraoperative tissue viability of human bowel. Surg Endosc. 2022 Mar;36(3):2192-2196. doi: 10.1007/s00464-021-08737-y. Epub 2021 Sep 22. PubMed 34550436 ↗
  • Khavanin N, Darrach H, Kraenzlin F, Yesantharao PS, Sacks JM. The Intra.Ox Near-Infrared Spectrometer Measures Variations in Flap Oxygenation That Correlate to Flap Necrosis in a Preclinical Rodent Model. Plast Reconstr Surg. 2021 May 1;147(5):1097-1104. doi: 10.1097/PRS.0000000000007894. PubMed 33835088 ↗
  • Gonzalez-Jacobo A, Chandler P, Martz J, Sherwinter D. Tissue Oximetry as a Potential Alternative to Indocyanine Green (ICG) Perfusion Assessment in Colorectal Anastomotic Cases. Surg Laparosc Endosc Percutan Tech. 2023 Apr 1;33(2):207-210. doi: 10.1097/SLE.0000000000001161. PubMed 36971520 ↗
  • Khavanin N, Almaazmi H, Darrach H, Kraenzlin F, Safar B, Sacks JM. Comparison of the ViOptix Intra.Ox Near Infrared Tissue Spectrometer and Indocyanine Green Angiography in a Porcine Bowel Model. J Reconstr Microsurg. 2020 Jul;36(6):426-431. doi: 10.1055/s-0040-1702163. Epub 2020 Feb 23. PubMed 32088921 ↗
  • Nguyen MB, Zhang N, Baranger J, Aguet J, Friedberg MK, Barron DJ, Honjo O, Mertens LL, Villemain O. Ultrafast Power Doppler for Detecting Intraoperative Myocardial Perfusion in Infants With Critical Congenital Heart Disease. JACC Adv. 2023 Apr 12;2(3):100290. doi: 10.1016/j.jacadv.2023.100290. eCollection 2023 May. No abstract available. PubMed 38939593 ↗
  • Said SM, Marey G, Hiremath G. Intraoperative fluorescence with indocyanine green in congenital cardiac surgery: Potential applications of a novel technology. JTCVS Tech. 2021 Feb 25;8:144-155. doi: 10.1016/j.xjtc.2021.02.026. eCollection 2021 Aug. PubMed 34401838 ↗
  • Goldman ME, Mindich BP. Intraoperative cardioplegic contrast echocardiography for assessing myocardial perfusion during open heart surgery. J Am Coll Cardiol. 1984 Nov;4(5):1029-34. doi: 10.1016/s0735-1097(84)80067-4. PubMed 6333444 ↗
  • Cyran SE, Kimball TR, Meyer RA, Bailey WW, Lowe E, Balisteri WF, Kaplan S. Efficacy of intraoperative transesophageal echocardiography in children with congenital heart disease. Am J Cardiol. 1989 Mar 1;63(9):594-8. doi: 10.1016/0002-9149(89)90905-3. PubMed 2919563 ↗
  • Nguyen MB, Zhang N, Mertens LL, Barron D, Honjo O, Venet M, Baranger J, Villemain O. Noninvasive assessment of myocardial perfusion using ultrafast ultrasound: clinical study for congenital heart disease. Eur Heart J Imaging Methods Pract. 2025 Jan 16;3(1):qyaf007. doi: 10.1093/ehjimp/qyaf007. eCollection 2025 Jan. PubMed 39974276 ↗
  • Congenital Heart Defects: What are Congenital Heart Defects? (2022). https://www.nhlbi.nih.gov/health/congenital-heart-defects.
  • Singh Y, Lakshminrusimha S. Perinatal Cardiovascular Physiology and Recognition of Critical Congenital Heart Defects. Clin Perinatol. 2021 Aug;48(3):573-594. doi: 10.1016/j.clp.2021.05.008. PubMed 34353581 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 23, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07361523
Collaborators
ViOptix Canada
Responsible party
Sitaram Emani (Principal Investigator (PI), Boston Children's Hospital) — Principal investigator
First posted
Jan 23, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Sitaram Emani, M.D.
Contact
Sitaram.Emani@CARDIO.CHBOSTON.ORG
617-355-7932
Vivian Nguyen, B.A.
Contact
Vivian.Nguyen@childrens.harvard.edu
617-355-7932

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion